- NuZee (NUZE) +21%.
- Starbox Group Holdings (STBX) +20% FY earnings call release
- Huadi International Group (HUDI) +16%.
- Zymeworks (ZYME) +12% overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma.
- CureVac (CVAC) +8% jumps as UBS upgrades to Buy on mRNA potential.